PepGen Reports Positive Early Data for DM1 Drug PGN-EDODM1, Confirms Next Cohort Enrollment

summarizeSummary

PepGen Inc. released an updated corporate presentation detailing positive safety and splicing correction data from the lowest dose of its PGN-EDODM1 multiple-ascending dose trial for Myotonic Dystrophy Type 1, and confirmed full enrollment for the next higher dose cohort.

check_boxKey Events

• Positive Clinical Data Reported

  PepGen presented favorable safety and promising splicing correction (mean 7.3%, or 22.9% excluding an outlier) and vHOT trends from the 5 mg/kg cohort of the FREEDOM2 MAD trial for PGN-EDODM1 in Myotonic Dystrophy Type 1 (DM1).

• Trial Progression Confirmed

  The company confirmed full enrollment for the 10 mg/kg multiple-ascending dose cohort of the FREEDOM2 trial, indicating continued advancement of the clinical program.

• Future Milestones Set

  PepGen anticipates reporting clinical results from the 10 mg/kg cohort in the second half of 2026 and from the 12.5 mg/kg cohort in 2027, providing a clear timeline for upcoming data readouts.

• Cash Runway Reaffirmed

  The company reiterated its strong cash runway, extending into the second half of 2027, which supports ongoing development activities through the FREEDOM2 12.5 mg/kg MAD readout.

auto_awesomeAnalysis

This 8-K provides a significant update on PepGen's lead drug candidate, PGN-EDODM1, for Myotonic Dystrophy Type 1. The detailed presentation of positive safety and efficacy trends from the lowest dose of the FREEDOM2 MAD trial is crucial, especially following the previously disclosed partial clinical hold. The successful enrollment of the next higher dose cohort and clear timelines for future data readouts provide a positive outlook and reduce uncertainty for investors in this nano-cap biotech. The reiterated cash runway also provides financial stability for these ongoing trials.